Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35354
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Torres J. | en |
dc.contributor.author | Feagan B.G. | en |
dc.contributor.author | Chande N. | en |
dc.contributor.author | MacDonald J.K. | en |
dc.contributor.author | Parker C.E. | en |
dc.contributor.author | East J.E. | en |
dc.contributor.author | Boyapati R.K. | en |
dc.date.accessioned | 2021-05-14T11:56:30Z | en |
dc.date.available | 2021-05-14T11:56:30Z | en |
dc.date.copyright | 2019 | en |
dc.date.created | 20200506 | en |
dc.date.issued | 2020-05-06 | en |
dc.identifier.citation | Inflammatory Bowel Diseases. 25 (3) (pp 472-478), 2019. Date of Publication: 01 Mar 2019. | en |
dc.identifier.issn | 1078-0998 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/35354 | en |
dc.description.abstract | A symposium organized by the Cochrane IBD Group and presented at the 2017 Digestive Disease Week annual meeting reviewed the recent literature on several controversial topics in inflammatory bowel disease (IBD) management including the efficacy of oral aminosalicylates for induction and maintenance of Crohn's disease (CD), the feasibility of drug withdrawal in patients with quiescent CD, and strategies for detecting colon cancer in patients with IBD. This article summarizes the data presented at that session.Copyright © 2018 Crohn's & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Oxford University Press | en |
dc.relation.ispartof | Inflammatory Bowel Diseases | en |
dc.subject.mesh | ulcerative colitis | - |
dc.subject.mesh | aminosalicylic acid | - |
dc.subject.mesh | corticosteroid | - |
dc.subject.mesh | mesalazine/ct | - |
dc.subject.mesh | mesalazine | - |
dc.subject.mesh | methylprednisolone | - |
dc.subject.mesh | olsalazine | - |
dc.subject.mesh | olsalazine/ct | - |
dc.subject.mesh | prednisone | - |
dc.subject.mesh | salazosulfapyridine | - |
dc.subject.mesh | remission | - |
dc.subject.mesh | Crohn Disease Activity Index | - |
dc.subject.mesh | diarrhea | - |
dc.subject.mesh | cancer susceptibility | - |
dc.subject.mesh | colon cancer | - |
dc.subject.mesh | Crohn disease | - |
dc.subject.mesh | drug efficacy | - |
dc.subject.mesh | drug safety | - |
dc.subject.mesh | inflammatory bowel disease | - |
dc.subject.mesh | interstitial nephritis | - |
dc.subject.mesh | pancreatitis | - |
dc.subject.mesh | pericarditis | - |
dc.subject.mesh | pleurisy | - |
dc.subject.mesh | Crohn disease | - |
dc.title | Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. | en |
dc.type | Review | en |
dc.identifier.affiliation | Gastroenterology and Hepatology | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/ibd/izy268 | - |
dc.publisher.place | United States | en |
dc.identifier.pubmedid | 30789982 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30789982] | en |
dc.identifier.source | 631555564 | en |
dc.identifier.institution | (East) Translational Gastroenterology Unit and Oxford NIHR Biomedical Research Centre, Experimental Medicine Division, Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom (Boyapati) Department of Gastroenterology, Monash Health, Melbourne, VIC, Australia (Torres) Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States (Torres) Hospital Beatriz Angelo, Gastroenterology Division, Loures, Portugal (Parker, Feagan) Robarts Clinical Trials Inc., London, ON, Canada (MacDonald, Chande, Feagan) Cochrane IBD Group, University of Western Ontario, London, ON, Canada (Chande, Feagan) Division of Gastroenterology, Department of Medicine, University of Western Ontario, London, ON, Canada (Feagan) Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON N6A 5B6, Canada | en |
dc.description.address | B.G. Feagan, Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON N6A 5B6, Canada. E-mail: brian.feagan@robartsinc.com | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | cancer detection colonoscopy Crohn's disease drug withdrawal ulcerative colitis | en |
dc.identifier.authoremail | Feagan B.G.; brian.feagan@robartsinc.com | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.